All In Biotech

Drug Trial Radar · NCT06211634

A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

A Phase 1/2, First-in-Human, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants With Glanzmann Thrombasthenia

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

57

Planned (sponsor's estimate)

Start

Dec 13, 2022

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Hemab ApSIndustry
Sponsor type
Industry
First posted
Jan 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 67 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia. The main questions it aims to answer are: * Parts A, B, and C: To determine the safety and tolerability of HMB-001 * Part A: To establish the dose level(s) and dosing interval(s) of HMB-001 to be investigated in Parts B and C * Parts B and C: To estimate the ability of HMB-001 to prevent the number and severity of bleeds Part A will assess differing singular doses of HMB-001 in small groups of participants. The dose administered to a newly enrolled participant (or groups of participants) may only increase if analysis of data from previous dosing shows it is safe to do so. The planned duration of participation in Part A is approximately 6 months, which consists of a Screening Period, an optional Run-in Observation Period, and a follow-up period of 8 weeks. Part B is similar to Part A as it involves testing different dose levels of HMB-001 in small groups of participants. However, in Part B, HMB-001 is given multiple times over a 3-month period, either weekly, every 2 weeks, or every 4 weeks. Part B consists of a Screening Period, a Run-in Observation Period, a 3-month Treatment Period, and a Safety Follow-up following the last dose of HMB-001. Part C is open to participants from Part B and consists of approximately a 18-month Treatment Period and a Safety Follow-up following the last dose of HMB-001.

Conditions

  • Glanzmann Thrombasthenia

Interventions

  • HMB-001Drug

    HMB-001 is a bispecific antibody being developed as a prophylactic treatment option to prevent and reduce bleeding events in patients with Glanzmann thrombasthenia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Safety as assessed by the incidence of treatment-emergent adverse events (TEAEs)Time frame: From baseline to Day 57
  2. Part A: Safety as assessed by the changes in physical examinations, vital signs, clinical laboratory assessments, and ECG parametersTime frame: From baseline to Day 57
  3. Part B: Safety as assessed by the incidence of treatment-emergent AEsTime frame: From baseline to Day 106/Early Termination (ET)/End of Study (EOS)
  4. Part B: Safety as assessed by the changes in physical examinations, vital signs, clinical laboratory assessments, and ECG parametersTime frame: From baseline to Day 106/ET/EOS
  5. Part B: Preliminary prophylactic effect of HMB-001 as assessed via Bleed frequency: annualized bleed rate (ABR)Time frame: From baseline to Day 106/ET/EOS
  6. Part B: Preliminary prophylactic effect of HMB-001 as assessed via Bleed frequency: annualized treated bleed rate (ATBR)Time frame: From baseline to Day 106/ET/EOS
  7. Part C: Safety as assessed by the incidence of treatment-emergent AEsTime frame: Day 99 to Day 687/Early Termination (ET)/ENdo of Study (EOS)
  8. Part C: Safety as assessed by the changes in physical examinations, vital signs, clinical laboratory assessments, and ECG parametersTime frame: Day 99 to Day 687/Early Termination (ET)/ENdo of Study (EOS)
  9. Part C: Preliminary prophylactic effect of HMB-001 as assessed via Bleed frequency: annual treated bleed rate (ATBR) and annualized bleed rate (ABR)Time frame: Day 99 to Day 687/Early Termination (ET)/ENdo of Study (EOS)

Locations

17 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California, San Diego (UCSD) (Part B/C)

    La Jolla, California

  • Tulane University Medical Center (Part B/C)

    New Orleans, Louisiana

  • Mayo Clinic - Rochester (Part B/C)

    Rochester, Minnesota

  • Hemophilia Center of Western Pennsylvania (HCWP) (Part B/C)

    Pittsburgh, Pennsylvania

  • Washington Institute for Coagulation (Part B/C)

    Seattle, Washington

  • University Hospital Leuven - Campus Gasthuisberg (Part B/C)

    Leuven, Belgium

  • AP-HP Hopital Bicetre (Part B/C)

    Le Kremlin-Bicêtre, France

  • AP-HM - Hopital de la Timone

    Marseille, France

  • AP-HP Hopital Necker-Enfants Malades (Part B/C)

    Paris, France

  • Azienda Ospedaliero-Universitaria Careggi (Part B/C)

    Florence, Italy

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano (Part B/C)

    Milan, Italy

  • Universitair Medisch Centrum Utrecht (Part B/C)

    Utrecht, Netherlands

  • Queen Elizabeth Hospital Birmingham (Part B/C)

    Birmingham, United Kingdom

  • Leeds Teaching Hospitals NHS Trust

    Leeds, United Kingdom

  • Richmond Pharmacology Ltd (Part A/B/C)

    London, United Kingdom

  • Royal Free London NHS Foundation Trust (Part B/C)

    London, United Kingdom

  • The Royal London Hospital (Part B/C)

    Whitechapel, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.